Ant Group Makes Trusted AI Solutions More Accessible to Support Industrial Collaboration in Digital Economy
14.9.2022 16:48:00 EEST | Business Wire | Press release
Ant Group today announced three initiatives to make trusted AI more accessible. This includes making its graph processing database TuGraph open source; launching an industrial-grade AI security testing platform; and unveiling a privacy-preserving computation open platform. Announced at the World Artificial Intelligence Conference (“WAIC”) in Shanghai, these actions aim to make trusted AI solutions more accessible to enable industrial multi-party collaborations in the digital economy.
A growing number of industries have been adopting AI technology at a fast pace, which has significantly increased demand for trusted multi-party collaboration solutions and AI systems that are secure, reliable and robust.
“We believe that Privacy-Preserving Computation, Blockchain, Graph-Processing Technology, Distributed Database and Green Computing are the fundamental technologies for a large-scale industrial application of AI in the digital economy. These fundamental technologies are critical for overcoming challenges arising from the surging demand for security and trust in multi-party industrial collaboration, surging need for data storage and energy consumption, as well as the rising complexity in managing relationships among different parties,” said Tao Wei, Vice President and Chief Technology Security Officer at Ant Group. “Ant Group has been continuously investing in the research and development of these technologies to facilitate more industrial collaborations in the digital economy.”
As part of the actions, Ant Group has also made TuGraph open source for global developers on Github. TuGraph is one of the key components in the Company’s large-scale graph-processing system and was jointly developed by Ant Group and Tsinghua University. The graph-processing technology has a wide range of applications, such as risk control, anti-fraud and knowledge graph.
TuGraph was awarded the World Leading Internet Scientific and Technology Achievements in 2021, and broke the throughput record in the audited results of the LDBC Social Network Benchmark (Interactive Workload) in August 2022.
Ant Group, China Academy of Information and Communications Technology (“CAICT”) and Tsinghua University also launched an industrial-grade AI security testing platform to provide developers a one-stop evaluation solution from adversarial tests to defense and reinforcements. This platform also helps developers recognize and predict model risks through a single click, building safer and more robust AI models and detect systemic risks in advance. The platform is embedded with independently developed adversarial-AI security computing engines, which can improve the computing performance by dozens of times. Meanwhile, the platform now offers robustness evaluation for global developers with more functions planned in the pipeline.
In July 2022, Ant Group made its privacy-preserving computation framework open source. The privacy computing platform released this time features a one-stop solution for industrial users to create privacy computation applications in various use cases, such as medical service, insurance claims, joint marketing and risk control. It also comes with the additional option to build applications without writing a single line of code.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220903005014/en/
Contact information
Media Inquiries
Zhumei Wang
zhumei.wzm@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom